AC
ACOR

Armistice Capital’s Acorda Therapeutics ACOR Stock Holding History

Armistice Capital’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,567
Closed -$8.05M – 58
2016
Q4 		$8.05M Sell
3,567
-1,000
-22% -$2.38M 1.9% 23
2016
Q3 		$11.4M Buy
4,567
+2,634
+136% +$7.86M 3.67% 4
2016
Q2 		$5.92M Sell
1,933
-1,050
-35% -$3.41M 2.25% 17
2016
Q1 		$9.47M Buy
2,983
+1,150
+63% +$4.77M 3.72% 8
2015
Q4 		$9.41M Sell
1,833
-1,650
-47% -$7.21M 3.36% 10
2015
Q3 		$11.1M Buy
3,483
+1,933
+125% +$7.5M 3.78% 9
2015
Q2 		$6.2M Buy
+1,550
New +$5.99M 2.23% 19

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Armistice Capital's ACOR Position: Q1 2017 in Review

Armistice Capital sold out of Acorda Therapeutics (ACOR) in Q1 2017, closing a stake of 3,567 shares — an estimated $8.05M sold.

Armistice Capital first reported a position in ACOR in Q2 2015 and held it in 7 quarters. The position peaked at $11.4M in Q3 2016. 178 funds tracked by Wall St. Rank hold ACOR as of Q1 2017.

  • Armistice Capital reported no remaining Acorda Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Armistice Capital sold 3,567 Acorda Therapeutics shares in Q1 2017, an estimated $8.05M.
  • Armistice Capital first reported a position in Acorda Therapeutics in Q2 2015 and held it in 7 quarters.
  • Armistice Capital's Acorda Therapeutics position peaked at $11.4M in Q3 2016.
  • 178 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2017.

Based on Armistice Capital's 13F filing for Q1 2017, filed 15 May 2017.